Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...